Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, comments on the management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric-antigen receptor T-cell (CAR-T) therapy for patients with acute lymphoblastic leukemia (ALL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Management of CRS and ICANS after CAR-T therapy for ALL
Теги
Speaker: Vipul ShethInstitution: Fred Hutchinson Cancer Research CenterEvent: EHA 2021Format: InterviewSubject: LeukemiaSubject: Acute Lymphoblastic LeukemiaMedicines: CAR-TMedicines: DexamethasoneField: TreatmentField: CAR-T & Cellular TherapyField: Immuno-OncologyField: Perspectivescytokine release syndromeCRSICANSimmune effector cell-associated neurotoxicity syndromechimeric antigen receptor T-cellALL